Atrix announced today that the company has signed an exclusive
marketing agreement with PharmaScience Inc., headquartered in Montreal, for the marketing and distribution of Atrix' professional dental products, including Atridox(R), Atrisorb(R) Free-Flow, and Atrisorb(R)-D periodontal products. In related news, Genmedix, Ltd, Atrix's marketing partner for Israel, has received a license to market Atridox in Israel, further expanding the opportunities for Atrix's dental products in this region.
Dr. Steve Garrett, president of Atrix's newly-formed dental division said, "PharmaScience is enthusiastic about marketing our innovative products. It has been a priority to restore distribution of our dental products in Canada and we are confident that PharmaScience will be an excellent partner."
Morris Goodman, chairman and founder of PharmaScience said, "These dental products have been well received by the Canadian dental community and we look forward to the opportunity to promote and expand the use of Atrix's dental products. As a leading distributor of proprietary and over-the-counter products, this new agreement fits well with our strategy to expand our growing organization into the professional oral care market."
In addition to marketing Atrix's dental products, PharmaScience will also distribute Periostat(R) in Canada for Atrix's U.S. marketing partner, CollaGenex Pharmaceuticals Inc., following marketing approval. In the U.S., Atridox and Periostat are often marketed in conjunction for optimal treatment of chronic adult periodontitis.
In related news, acquisition of a license to market Atridox in Israel by
Genmedix, Ltd, a Merck KgaA company, continues to expand the global distribution of Atrix's dental products. Genmedix, one of the leading marketers of prescription products to oral care professionals in Israel, currently markets the Atrisorb guided tissue regeneration barrier products for Atrix.
For further information, please contact: Danette R.M. Meyer, Ph.D.,
Director, Investor Relations of Atrix Laboratories, Inc., +1-970-482-5868, [email protected]; or investors, Robert Jaffe of PondelWilkinson MS&L, +1-310-207-9300, [email protected], for Atrix Laboratories, Inc.
